Q-omics provides the consensus-scored MCCD1 profile across patient tissues and cancer cell-line models. MCCD1 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, MCCD1 is differentially expressed in 7, with the highest sampling consensus in KIRC. Additionally, MCCD1 RNA expression shows 7,863 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight HNSC, KIRC, and UVM as cancer lineages where MCCD1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MCCD1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MCCD1 survival associations across molecular data types. MCCD1 RNA expression shows survival associations in the most cancer types (18), followed by mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MCCD1 RNA expression–survival associations across cancer types. High MCCD1 expression shows unfavorable associations in MESO, SKCM, DLBC and UCEC, but favorable associations in HNSC and BRCA. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .004). Together, the overview and detailed table identify HNSC as the clearest survival context for MCCD1 RNA expression.
This table summarizes MCCD1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for MCCD1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MCCD1 shows lower tumor expression in KIRC, KIRP, KICH and BRCA and higher tumor expression in LIHC and UCEC. The KIRC box plot shows higher MCCD1 RNA expression in normal versus tumor tissue (log2 FC = −4.863, t-test p < 0.001).
This table shows molecular features associated with MCCD1 in patient tissues and cancer cell lines. In patient samples, MCCD1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, MCCD1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and BLOOD_Leukemia.
